Navigation Links
ISTA Pharmaceuticals Highlights Clinical Data from REMURA™ Phase 2 Study Presented at the 6th International Conference on the Tear Film & Ocular Surface
Date:9/27/2010

scores were recorded prior to the first treatment with REMURA and were compared to scores at Day 14, Day 42 and Day 52.

Authors of the posters were Simon P. Chandler, Ph.D., James A. Gow, M.D. and Timothy R. McNamara, Pharm.D. of ISTA Pharmaceuticals, Inc., Irvine, CA, USA; Sheri L. Rowen, M.D., of the Mercy Medical Eye and Cosmetic Surgery Center, Baltimore, MD, USA; and Neal A. Sher, M.D., F.A.C.S., Partner, Eye Care Associates, Minneapolis, MN, USA.

ISTA recently announced the Company has initiated its REMURA Phase 3 clinical study program.  Two Phase 3 studies to evaluate the efficacy and safety of REMURA are being conducted under a Special Protocol Assessment (SPA) agreed upon with the U.S. Food and Drug Administration (FDA), and two remaining Phase 3 safety studies are the subject of additional SPAs currently under review by the FDA.  ISTA anticipates starting the remaining safety studies later this year and reporting results for the first two Phase 3 efficacy and safety studies in the middle of 2011.

ABOUT DRY EYE DISEASE

Dry eye occurs when there is an imbalance of tears that provides moisture and lubrication to the eye, which can result in pain, itching, redness, blurry vision, light sensitivity and/or a gritty sensation or feeling of sand in the eye.  Causes for dry eye include environmental conditions such as air conditioning, smoke and dust, aging and menopause, side-effects from antihistamines and birth control pills, Sjogren's syndrome, rheumatoid arthritis and structural problems with the eye lid's ability to close. Left untreated, dry eye can lead to abrasions on the surface of the eye and damage to the cornea. Current treatments include artificial tears and ointments, topical steroids, a topical immunomodulator that is the only approved prescription eye drop treatment, and punctal occlusion (closing or plugging of tear drains).  

ABOUT REMURA AND BROMFENAC OPHTHALMIC SOLUTION'/>"/>

SOURCE ISTA Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Fourth Quarter Fiscal 2010
2. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
3. TOPICA Pharmaceuticals Announces Sublicensing Agreement for Tinea Indication
4. Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference
5. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
6. Edimer Pharmaceuticals and CMC Biologics Announce Agreement to Manufacture EDI200 Recombinant Protein
7. Transdel Pharmaceuticals to Present at Rodman & Renshaw 12th Annual Healthcare Conference
8. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare and Baird Global Healthcare Conferences
9. Access Pharmaceuticals Presents at American Chemical Society Annual Fall Meeting in Boston, MA
10. Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402.
11. NanoSmart™ Pharmaceuticals, Inc. Receives Patent Allowance for Tumor Targeting Platform Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... October 31, 2014 Jeffrey T. Manuel, ... Historical Studies within the College of Arts and Sciences, ... record the history of alcohol-based fuels in Illinois. ... others have been working to build Illinois’ biofuels industry ... overlooked aspect of the state's agricultural and business history. ...
(Date:10/31/2014)... 2014 ENVIRON , an ... today that Dr. Harvey Clewell III has rejoined ... work closely with senior professionals in ENVIRON’s Health ... serve at The Hamner Institutes for Health Sciences ... where he is Director, Center for Human Health ...
(Date:10/30/2014)... 2014 Investor-Edge has initiated coverage ... ONVO), Medivation Inc. (NASDAQ: MDVN ), Pharmacyclics ... (NYSE MKT: SYN), and Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD). ... at: http://investor-edge.com/register . On Wednesday, October ... 0.33%, the Dow Jones Industrial Average declined 0.18%, to ...
(Date:10/30/2014)... 30, 2014 SoundConnect , ... offers Office 365 end users the key to ... phone system by adding voice enablement and hybrid ... Lync Online, a communication tool that includes presence, ... hosted voice, O365 becomes a comprehensive unified communications ...
Breaking Biology Technology:SIUE History Prof Manuel Working on Biofuels Book with NCERC 2SIUE History Prof Manuel Working on Biofuels Book with NCERC 3Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 2Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 2Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 4Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 5SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 2SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 3
... Calif., Feb. 4 Arryx, Inc.,announced the addition ... Holographic Optical Trapping ("HOT") product line. The HOTkit,Complete ... events, and now, through the power of light, ... The HOTkit Complete was unveiled February 4 ...
... HORSHAM, Pa., Feb. 4 Centocor, Inc. announced ... (CNTO 1275),has been accepted for review by the ... of adult patients with chronic moderate to severe ... with a novel,mechanism of action that targets the ...
... HAVEN, Conn., Feb. 4 VION,PHARMACEUTICALS, INC. (Nasdaq: ... the Company,s senior management team as Vice President,Medical., ... pleased,to have Bill Hahne joining Vion in medical affairs. ... will be extremely useful to our,efforts to file a ...
Cached Biology Technology:Arryx Launches HOTkit(TM) Complete for Dynamic, Scientific Manipulation of Microscopic Elements 2Arryx Launches HOTkit(TM) Complete for Dynamic, Scientific Manipulation of Microscopic Elements 3Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA 2Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA 3Vion Pharmaceuticals Adds William Hahne, M.D. to Senior Management Team 2Vion Pharmaceuticals Adds William Hahne, M.D. to Senior Management Team 3
(Date:10/29/2014)... open for the Society of Interventional Radiology,s ... is the one place where interventional radiologists, ... care professionals can come together to find ... being presented, discussed and tested. , ... image-guided medicine, SIR 2015 will feature essential ...
(Date:10/29/2014)... and industrial products are in the environment – and ... them, scientists have yet to determine whether they cause ... doing that by estimating which substances people are exposed ... the ACS journal Environmental Science & Technology . ... risks to human health of any given substance depend ...
(Date:10/29/2014)... LANSING, Mich. – As bodies decompose, their types ... the clues they provide could mean the difference ... , Michigan State University is using a more ... help Detroit death-scene investigators examine these changing populations. ... as geographical location of death, gender, race, socioeconomic ...
Breaking Biology News(10 mins):SIR 2015: Interventional radiology shapes tomorrow's medicine 2MSU partners with Detroit to investigate death scenes 2
... of California, San Diego has discovered a molecule in ... or Bt toxin--a pesticide produced by bacteria and widely ... to ward off insect pests. , Their findings should ... prevent insects, which the researchers believe also possess the ...
... scientific world has accepted for more than 100 ... by their grandparents, bypassing genetic abnormalities carried by ... have hidden templates containing genetic information from the ... offspring, even though the traits aren't evident in ...
... to coax mouse stem cells to transform themselves into fat ... naturally do in the body. , While other studies have ... cells never completely functioned in the same way they do ... biologic components that all cells require to do their work. ...
Cached Biology News:UCSD discovery may help extend life of natural pesticide 2UCSD discovery may help extend life of natural pesticide 3Plants defy Mendel's inheritance laws, may prompt textbook changes 2Plants defy Mendel's inheritance laws, may prompt textbook changes 3Tiny scaffolding allows stem cells to become working fat cells 2Tiny scaffolding allows stem cells to become working fat cells 3
...
Tan solid. A glycoside used to permeabilize cellular membranes. Exhibits hemolytic activity. Contaminants: ash: ≤10%. Soluble in H 2 O. pH 4.4 - 4.6. RTECS VQ1400000, CAS 8047-15-2. References:...
...
... utilizes a silica based spin filter membrane to ... desired DNA band is cut from an agarose ... unit. The gel slice is melted irreversibly in ... is bound to the silica spin filter membrane ...
Biology Products: